About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
IDEAYA Biosciences image

IDEAYA Biosciences

Rank#3788
Market Cap3.60B
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Historyarrow

IDEAYA was founded in 2017 and is headquartered in South San Francisco, California. In December, 2019 they closed venture capital financing of $100 million. IDEAYA has established collaborations with leading research institutions and biopharmaceutical companies, including Merck, GSK/Tesaro, and MD Anderson Cancer Center at the University of Texas.

Missionarrow
IDEAYA Biosciences' mission is to develop new targeted oncology therapies by leveraging a deep understanding of the genetic drivers of cancer and combining breakthrough science with cutting-edge technologies.
Visionarrow
IDEAYA's vision is to create a future in which cancer patients have more meaningful options and can benefit from transformative, personalized therapies.
Referencesarrow

https://in.investing.com/equities/ideaya-biosciences-inc

https://finance.yahoo.com/quote/IDYA/profile?p=IDYA

https://www.crunchbase.com/organization/ideaya-biosciences

https://sec.report/CIK/0001676725

https://companiesmarketcap.com/

https://www.ideayabio.com

Share

Leadership team
M
Mr. Yujiro S. Hata (Co-Founder, CEO, Pres & Director)
M
Mr. Paul A. Stone (Sr. VP, CFO & Principal Accounting Officer)
D
Dr. Michael A. White Ph.D. (Sr. VP & Chief Scientific Officer)
Products / Services
Biotechnology, Health Care, Therapeutics
Number of Employees
50 - 100
Address
South San Francisco, California, United States
Established
2015-01-01
Company Registration
SEC CIK number: 0001676725
Revenue
20M - 100M
Traded as
IDYA
Website
https://www.ideayabio.com
Social Media
linkedinfacebook
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo